{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:59Z","timestamp":1784977259937,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04235-6","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:14:18Z","timestamp":1770462858000},"page":"3277-3286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in Spain"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7303-707X","authenticated-orcid":false,"given":"Sigfredo Elias","family":"Romero Zoghbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"L\u00f3pez Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahams","family":"Ocanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sanz-Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel John","family":"Thuissard - Vasallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andreu V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Laria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Fern\u00e1ndez Ibiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Andreescu Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evita","family":"Krumina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Dzhugashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Alberto","family":"Glar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Castalia","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Begara","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Gonz\u00e1lez Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ristori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Escarlata","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Bezares Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Aakki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Garc\u00eda Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Garc\u00eda Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"20","key":"4235_CR1","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1001\/jama.2024.6729","volume":"28","author":"E Harris","year":"2024","unstructured":"Harris E. Prostate cancer cases might rise to 3 million globally by 2040. JAMA. 2024;28(20):1698. https:\/\/doi.org\/10.1001\/jama.2024.6729. (PMID: 38700857).","journal-title":"JAMA"},{"issue":"3","key":"4235_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2024.12.007","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Jemal A, Torre LA, Soerjomataram I, Bray F. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2025;87(3):283\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2024.12.007.","journal-title":"Eur Urol"},{"issue":"17","key":"4235_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"27","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;27(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122. (Epub 2023 Mar 11. PMID: 36912538).","journal-title":"N Engl J Med"},{"issue":"1","key":"4235_CR4","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"1","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;1(1):e17-24. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.075. (Epub 2011 Feb 15. PMID: 21324610).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"4235_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4. (PMID: 27339115; PMCID: PMC4961874).","journal-title":"Lancet Oncol"},{"issue":"17","key":"4235_CR6","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"10","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;10(17):1884\u201390. https:\/\/doi.org\/10.1200\/JCO.2016.71.7397. (Epub 2017 Mar 15. PMID: 28296582).","journal-title":"J Clin Oncol"},{"issue":"10196","key":"4235_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"3","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;3(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6. (Epub 2019 Jun 18. PMID: 31227373).","journal-title":"Lancet"},{"key":"4235_CR8","doi-asserted-by":"crossref","unstructured":"Nilsson P, Gunnlaugsson A, Beckman L, Widmark A, Fransson P, Hoyer M, et al (2025) Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321). Presented at: ESTRO 2025 congress; 2025 May 3\u20137; Vienna, Austria. Abstract S4414, Presentation 4981","DOI":"10.1016\/S0167-8140(25)04191-X"},{"issue":"4","key":"4235_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"15","author":"WC Jackson","year":"2019","unstructured":"Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;15(4):778\u201389. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.051. (Epub 2019 Apr 6. PMID: 30959121; PMCID: PMC6770993).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4235_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijrobp.2024.09.052","volume":"1","author":"C Zamboglou","year":"2025","unstructured":"Zamboglou C, Arcangeli S, Kamran SC. Stereotactic body radiation therapy for prostate cancer is getting mature: 10-year outcomes from 3 prospective trials. Int J Radiat Oncol Biol Phys. 2025;1(2):331\u20132. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.052. (PMID: 39824572).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4235_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020;147:92\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.015. (Epub 2020 Apr 1 PMID: 32247206).","journal-title":"Radiother Oncol"},{"key":"4235_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110568","volume":"201","author":"C Draulans","year":"2024","unstructured":"Draulans C, Haustermans K, Pos FJ, van der Heide UA, De Cock L, van der Voort van Zyp J, et al. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024;201:110568. https:\/\/doi.org\/10.1016\/j.radonc.2024.110568. (Epub 2024 Oct 2 PMID: 39362607).","journal-title":"Radiother Oncol"},{"key":"4235_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-025-02598-8","author":"B De Cooman","year":"2025","unstructured":"De Cooman B, Debacker T, Adams T, Lamberts G, De Troyer B, Claessens M, et al. Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis. Radiat Oncol. 2025. https:\/\/doi.org\/10.1186\/s13014-025-02598-8. (PMID: 39985052; PMCID: PMC11846345).","journal-title":"Radiat Oncol"},{"key":"4235_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2025.501798","author":"SE Romero Zoghbi","year":"2025","unstructured":"Romero Zoghbi SE, L\u00f3pez Campos F, Sanz-Rosa D, Fern\u00e1ndez Ibiza J, Thuissard-Vasallo IJ, Andreu-V\u00e1zquez C, et al. Acute toxicity of SBRT in localized prostate cancer: a Spanish multicenter study. Actas Urol\u00f3gicas Espa\u00f1olas (English Edition). 2025. https:\/\/doi.org\/10.1016\/j.acuroe.2025.501798. (Epub ahead of print. PMID: 40633664).","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"},{"key":"4235_CR15","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): prostate cancer. Version 2.2025. Plymouth meeting (PA): NCCN; 2025. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459"},{"issue":"2","key":"4235_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jicru\/ndx017","volume":"14","author":"International Commission on Radiation Units and Measurements","year":"2017","unstructured":"International Commission on Radiation Units and Measurements, ICRU. Prescribing, recording, and reporting of stereotactic treatments with small photon beams. ICRU Report 91. J Int comm Radiat Units Meas. 2017;14(2):1\u2013160. https:\/\/doi.org\/10.1093\/jicru\/ndx017.","journal-title":"J Int comm Radiat Units Meas"},{"issue":"1","key":"4235_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1353-6","volume":"9","author":"S Scobioala","year":"2019","unstructured":"Scobioala S, Kittel C, Elsayad K, Kroeger K, Oertel M, Samhouri L, et al. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma. Radiat Oncol. 2019;9(1):143. https:\/\/doi.org\/10.1186\/s13014-019-1353-6. (PMID: 31399115; PMCID: PMC6689170).","journal-title":"Radiat Oncol"},{"issue":"1","key":"4235_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","volume":"104","author":"MJ Zelefsky","year":"2019","unstructured":"Zelefsky MJ, Kollmeier M, McBride S, Varghese M, Mychalczak B, Gewanter R, et al. Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019;104(1):42\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.045. (Epub 2019 Jan 4. PMID: 30611838; PMCID: PMC7525798).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4235_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.935310","volume":"29","author":"DB Fuller","year":"2022","unstructured":"Fuller DB, Crabtree T, Kane BL, Medbery CA, Pfeffer R, Gray JR, et al. High dose \u201cHDR-like\u201d prostate SBRT: psa 10-year results from a mature, multi-institutional clinical trial. Front Oncol. 2022;29:935310. https:\/\/doi.org\/10.3389\/fonc.2022.935310. (PMID: 35965547; PMCID: PMC9373838).","journal-title":"Front Oncol"},{"issue":"24","key":"4235_CR20","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1001\/jama.2024.6695","volume":"25","author":"LF Newcomb","year":"2024","unstructured":"Newcomb LF, Schenk JM, Zheng Y, Liu M, Zhu K, Brooks JD, et al. Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer. JAMA. 2024;25(24):2084\u201393. https:\/\/doi.org\/10.1001\/jama.2024.6695. (PMID: 38814624; PMCID: PMC11140579).","journal-title":"JAMA"},{"issue":"3","key":"4235_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12094-015-1371-2","volume":"18","author":"R Mazzola","year":"2016","unstructured":"Mazzola R, Fersino S, Fiorentino A, Ricchetti F, Giaj Levra N, Di Paola G, et al. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy. Clin Transl Oncol. 2016;18(3):317\u201321. https:\/\/doi.org\/10.1007\/s12094-015-1371-2. (Epub 2015 Aug 7. PMID: 26250766).","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"4235_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2(2):e188006. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.8006. (PMID: 30735235; PMCID: PMC6484596).","journal-title":"JAMA Netw Open"},{"issue":"4","key":"4235_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040759","volume":"13","author":"R Foerster","year":"2021","unstructured":"Foerster R, Zwahlen DR, Buchali A, Tang H, Schroeder C, Windisch P, et al. Stereotactic body radiotherapy for high-risk prostate cancer: a systematic review. Cancers (Basel). 2021;13(4):759. https:\/\/doi.org\/10.3390\/cancers13040759. (PMID: 33673077; PMCID: PMC7918664).","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4235_CR24","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","volume":"41","author":"J Le Guevelou","year":"2023","unstructured":"Le Guevelou J, Bosetti DG, Castronovo F, Angrisani A, de Crevoisier R, Zilli T. State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature. World J Urol. 2023;41(11):3287\u201399. https:\/\/doi.org\/10.1007\/s00345-023-04579-6. (Epub 2023 Sep 5. PMID: 37668718; PMCID: PMC10632210).","journal-title":"World J Urol"},{"issue":"6","key":"4235_CR25","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.urology.2013.01.047","volume":"81","author":"K Kalakota","year":"2013","unstructured":"Kalakota K, Liauw SL. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology. 2013;81(6):1196\u2013201. https:\/\/doi.org\/10.1016\/j.urology.2013.01.047. (Epub 2013 Mar 26. PMID: 23540863).","journal-title":"Urology"},{"key":"4235_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100907","volume":"51","author":"JL Gu\u00e9velou","year":"2024","unstructured":"Gu\u00e9velou JL, Sargos P, Ost P, Alongi F, Arcangeli S, Berlin A, et al. Urethra-sparing prostate cancer radiotherapy: current practices and future insights from an international survey. Clin Transl Radiat Oncol. 2024;51:100907. https:\/\/doi.org\/10.1016\/j.ctro.2024.100907. (PMID: 39845565; PMCID: PMC11751415).","journal-title":"Clin Transl Radiat Oncol"},{"issue":"10","key":"4235_CR27","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4235_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","volume":"109","author":"CR King","year":"2013","unstructured":"King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217\u201321. https:\/\/doi.org\/10.1016\/j.radonc.2013.08.030. (Epub 2013 Sep 20. PMID: 24060175.).","journal-title":"Radiother Oncol"},{"issue":"1 Suppl","key":"4235_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.06.2859","volume":"123","author":"A Romei","year":"2025","unstructured":"Romei A, Nicosia L, Orsatti C, Allegra AG, Pastorello E, Ricchetti F, et al. Characteristics and prognostic implications of PSA bounce in prostate cancer patients treated with stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys. 2025;123(1 Suppl):e598\u2013e599. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.2859.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4235_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ijrobp.2023.05.004","volume":"117","author":"BA Morris","year":"2023","unstructured":"Morris BA, Holmes EE, Anger NJ, Cooley G, Schuster JM, Hurst N, et al. Toxicity and patient-reported quality-of-life outcomes after prostate stereotactic body radiation therapy with focal boost to magnetic resonance imaging-identified prostate cancer lesions: results of a phase 2 trial. Int J Radiat Oncol Biol Phys. 2023;117(3):613\u201323. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.004. (Epub 2023 May 12. PMID: 37179035).","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04235-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04235-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04235-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:22Z","timestamp":1784975362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04235-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4235"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04235-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interest regarding any aspect of the manuscript.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional research committee (approval No. 5585) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Given the retrospective design and use of anonymized data, the Ethics Committee waived the requirement for individual informed consent.","order":2,"name":"Ethics","label":"Ethical Approval and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}